WILMINGTON, Mass., March 6, 2012 (GLOBE NEWSWIRE) -- DUSA Pharmaceuticals, Inc.® (Nasdaq:DUSA), a dermatology company that is developing and marketing its Levulan® Photodynamic Therapy (PDT) platform, reported today its corporate highlights and financial results for the fourth quarter and full year ended December 31, 2011.
